FDA Determines Regulatory Review Period for TRULANCE Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for TRULANCE, a human drug product, as required by law after receiving a patent extension application from the US Patent and Trademark Office (USPTO).